Entrop

Entrop has a direct activating effect on the integrative function of the brain.

The drug helps improve mental performance and concentration, simplifies learning, consolidates memory, increases the resistance of brain tissue to toxic effects and hypoxia. In addition, it also has an anxiolytic and anticonvulsant effect, normalizes the processes of slowing down and activating the central nervous system, and has a positive effect on mood.

Indications Entrop

It is used for diseases of the central nervous system of various origins, against the background of which a decrease in motor activity and a weakening of intellectual and mnestic activity are observed:

• neurotic conditions in which there is a disorder of memory, attention and assimilation of received information, fatigue, lethargy and weakening of psychomotor function;
• mild to moderate depression;
• syndromes of a psychoorganic nature, accompanied by apathetic-abulic symptoms and mental-mnestic disorders, as well as sluggish apathetic states that arise in the case of schizophrenia;
• convulsive states;
• chronic alcoholism (to relieve symptoms of depression, asthenia, mental and memory disorders).

It is prescribed to prevent hypoxia, increase stress resistance, stabilize the functional state in extreme situations at work, prevent fatigue and increase physical and intellectual performance, and in addition to this, to normalize the daytime biorhythm and invert the sleep/wake period.

Release form

The medicinal substance is released in tablets of 0.05 and 0.1 g, 10 pieces per blister pack; there are 1-2 such packs per box.

Pharmacodynamics

The drug has a beneficial effect on cerebral circulation and metabolism, stimulates oxidation-reduction processes, increases the body's energy capacity by utilizing glucose, and improves regional blood circulation processes within ischemic brain areas. Increases serotonin, dopamine, and norepinephrine levels within the brain, does not change GABA values, is not synthesized with GABA-α and GABA-β endings, and has no significant effect on spontaneous brain bioelectrical activity.

The drug does not affect the function of the cardiovascular system and respiration, has a weak diuretic effect, and has an anorexigenic effect in case of course use.

The stimulating activity of Entrop is associated with its ability to moderately affect motor function, increase physical performance, significant antagonism to the cataleptic effect of neuroleptics, and, in addition, with a weakening of the hypnotic effect of hexenal and ethyl alcohol.

The moderate psychostimulating effect of the drug develops mainly in the ideational sphere. This effect is combined with an anxiolytic effect, improves mood and has some analgesic activity, increasing the pain threshold.

The adaptogenic effect of phenylpiracetam increases the body's resistance to stress during excessive physical and mental stress, hypokinesia, low temperature, severe fatigue, and immobilization.

The use of the drug causes an improvement in vision - the visual field expands and acuity increases.

Phenylpiracetam helps improve blood circulation in the legs. This element also stimulates the production of antibodies (as a reaction to the use of an antigen), which allows us to conclude that it has immunostimulating properties; however, it does not cause immediate intolerance and does not correct allergic skin inflammation reactions that occur when using a foreign protein.

The course use of the drug does not cause the development of tolerance, drug dependence or withdrawal syndrome.

The effect of Entrop begins after the introduction of a single dose, which is extremely important in an extreme situation.

The drug does not have a mutagenic, embryotoxic, teratogenic or carcinogenic effect. It has a low toxicity index, experimentally it has been found that the lethal dose is 0.8 g/kg.

Pharmacokinetics

The drug is absorbed at high speed, passes into various tissues and organs, easily overcomes the BBB. The level of absolute bioavailability of the drug after oral administration is 100%. The Cmax indicator is noted after 60 minutes; the half-life is 3-5 hours.

The drug does not participate in metabolic processes and is excreted unchanged. Approximately 40% of the drug is excreted in urine, and the remaining 60% - in sweat and bile.

Dosing and administration

The drug should be taken orally, after meals. The portion size and duration of therapy are selected individually, taking into account the patient's condition.

The average 1-time portion size is 0.15 g (0.1-0.25 g), the average daily dosage is 0.25 g (0.2-0.3 g). A maximum of 0.75 g of the medicine is allowed per day. The daily dosage of up to 0.1 g must be taken at one time (in the morning), and portions over 0.1 g are divided into 2 doses.

The duration of therapy varies between 0.5-3 months. On average, it lasts 1 month. If necessary, after 1 month, the cycle can be repeated (consult your doctor first).

To increase performance – 1-time intake in the morning of 0.1-0.2 g of the drug over a period of 14 days (for athletes – 3 days).

For individuals with alimentary-constitutional obesity, 1-2 months of therapy is recommended in a dose of 0.1-0.2 g per day (taken in the morning).

The medicine cannot be used after 15:00.

• Application for children

The medication is not prescribed in pediatrics.

Use Entrop during pregnancy

Entrop is not used during breastfeeding and pregnancy.

Contraindications

Contraindicated for use in case of severe intolerance to the components of the drug.

Side effects Entrop

Main side effects:

• problems with the functioning of the central nervous system: sometimes irritability, aggression, anxiety, dizziness and headaches appear, as well as tearfulness, insomnia, sleep disorders and drowsiness. Occasionally, an obsessive state, hypomania, depression, temporary hallucinations, apathy and weakness develop;
• dysfunction of the cardiovascular system: sometimes there is a potentiation of signs of coronary insufficiency and an increase in blood pressure values;
• allergy symptoms: sometimes epidermal itching and rashes appear. Occasionally hyperkeratosis in the palms and hyperemia develop. Quincke's edema or urticaria may appear;
• Gastrointestinal disorders: dysgeusia or xerostomia occasionally occur.

When using the drug after 15:00, insomnia may develop. In some patients, hyperemia of the epidermis, psychomotor agitation, or a feeling of warmth may develop during the first 1-3 days of using the drug.

Overdose

In case of poisoning, side effects may be potentiated.

Symptomatic procedures are performed.

Interactions with other drugs

Entrop is able to potentiate the activity of antidepressants, drugs that stimulate the central nervous system, and nootropic drugs. It also prolongs and potentiates the effect of antiparkinsonian, narcotic and hypnotic substances.

Storage conditions

Entrop must be stored in a dark and dry place; temperature indicators - no more than 25°C.

Shelf life

Entrop can be used within a 4-year period from the date of manufacture of the medicinal product.

Analogues

Analogues of the medication are Cortexin and Kindinorm.